| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.09 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.12 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.12 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.25 | KE:352 | N/A, Neurodegeneration |
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:352 | N/A, Neurodegeneration |
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.17 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.22 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.22 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.14 | KE:1514 | Neurodegeneration |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.1 | KE:352 | N/A, Neurodegeneration | |
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.22 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.18 | KE:2121 | decreased, Intellectual Quotient | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:341 | Impairment, Learning and memory |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.08 | KE:341 | Impairment, Learning and memory | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:341 | Impairment, Learning and memory | |
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:341 | Impairment, Learning and memory |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:2121 | decreased, Intellectual Quotient |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.